Lilly(Eli) & Company
NYSE: LLY
$789.32
+$34.32 (+4.5%)
Closing Price on November 26, 2024
LLY Articles
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include Cheniere, Cisco, Eli Lilly, Intel, Kroger, Nokia, Rite Aid, Roku, Teva Pharmaceuticals, Tyson Foods, Walgreens Boots...
Published:
Last Updated:
The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
Published:
Last Updated:
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Published:
Last Updated:
The October 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
Here are 13 featured spin-offs already underway and potential spin-offs that could be seen in 2017 and into 2018 that could radically change how Wall Street and Main Street evaluate companies ahead.
Published:
Last Updated:
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
Published:
Last Updated:
These four top companies all have data that could move the shares the rest of this year and into 2018. All have been around for years and will remain sector leaders for years to come.
Published:
Last Updated:
With Eli Lilly making a huge headline investment in a cancer vaccine, 24/7 Wall St. wanted to look under the hood to see what this deal really entails.
Published:
Last Updated:
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Alphabet, Check Point Software, Chesapeake Energy, Chevron, Intel, MannKind, Schlumberger and Transocean.
Published:
Last Updated:
The September 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, Bristol-Myers, Eli Lilly, First Solar, Generac, Oracle, Sirius XM, Southwest and Wendy's.
Published:
Last Updated: